Researchers enable simultaneous use of two genetic codes

Scientists have announced a breakthrough that could make editing the genetic code more accessible than ever before. The new approach, unveiled at a recent biotechnology conference, builds on the CRISPR‑Cas system but introduces a streamlined workflow that reduces the number of steps and reagents required to modify DNA in living cells.

The technique employs a redesigned guide‑RNA scaffold combined with a highly efficient, engineered nuclease that can perform base conversions without creating double‑strand breaks. In laboratory tests, the system achieved precise single‑base edits in human cell lines with a success rate exceeding 90 %, while minimizing off‑target activity. Because the method eliminates the need for donor DNA templates and complex delivery vehicles, researchers can now carry out targeted edits in a single transfection, accelerating both basic research and therapeutic development.

If the platform’s performance translates to in‑vivo models, it could shorten the timeline for gene‑therapy trials and broaden the range of diseases that can be addressed at the DNA level. The simplified protocol also opens the door for smaller research groups and clinical laboratories to adopt advanced genome‑editing tools, potentially expanding the reach of precision medicine and functional genomics studies worldwide.